Lupus Nephritis from Bench to Bedside

References

1. Petri M, Fava A, Atta M, et al. Redefining when to biopsy the kidney in patients with SLE [abstract: 0772]. Arthritis Rheumatol. 2025;77(suppl 9).
2. De Rosa M, Azzato F, Toblli JE, et al. A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy. Kidney Int. 2018 Oct;94(4):788–794.
3. Fava A, Buyon J, Magder L, et al. Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis. JCI Insight. 2024 Jan 23;9(2):e172569.
4. Lee CY, Taghavi S, Zhang S, et al. Urinary Tenascin C Predicts Kidney Function Loss in Lupus Nephritis [abstract 0851]. Arthritis Rheumatol. 2025 Oct;77(suppl 9).
5. Fava A, Concoff A, O’Malley T, et al. A urinary biomarker panel to predict the probability of histologically active lupus nephritis [abstract 1642]. Arthritis Rheumatol. 2024 Oct; 76(suppl 9).
6. Sammaritano LR, Askanase A, Bermas BL, et al. 2024 American College of Rheumatology guideline for the screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2025 Sep;77(9):1045–1065.
7. Anders HJ. Re-biopsy in lupus nephritis. Ann Transl Med. 2018 Nov;6(suppl 1):S41.
8. Arriens C, Teng YKO, Ginzler EM, et al. Update on the efficacy and safety profile of voclosporin: An integrated analysis of clinical trials in lupus nephritis. Arthritis Care Res. 2023 Jul;75(7):1399–1408.
9. Rovin BH, Furie R, Teng YKO, et al. A secondary analysis of the belimumab international study in lupus nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney Int. 2022 Feb;101(2):403–413.
10. Furie RA, Rovin BH, Garg JP, et al. Efficacy and safety of obinutuzumab in active lupus nephritis. N Engl J Med. 2025 Apr 17;392(15):1471–1483.